Studies of type I SMA patients, conducted before the advent of DMTs, demonstrated low levels of both myostatin and activin receptor, with a reduced therapeutic potential of myostatin inhibitors [11]. The gene discussed is MSTN; the disease is spinal muscular atrophy, type 1.